SOPHiA GENETICS Partners with Jessa Ziekenhuis to Enhance Precision Oncology in Belgium
SOPHiA GENETICS, a leading cloud-native healthcare technology company, announced a major partnership with Jessa Ziekenhuis in Hasselt, Belgium, aimed at enhancing genomic testing and oncology research for cancer patients throughout the country. This collaboration will see the implementation of SOPHiA GENETICS' fully automated, cloud-native solutions tailored to oncology needs, allowing Jessa Ziekenhuis to unify workflows, accelerate insights, and improve patient care. The partnership is expected to reduce hands-on time by 30-50%, decrease costs by up to 25%, and speed up testing turnaround times. This initiative marks an important investment in personalized medicine, supporting advanced oncological care and research in Belgium.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: NE65965) on September 05, 2025, and is solely responsible for the information contained therein.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。